Literature DB >> 28177171

Increased survivability of ischemic skin flap tissue in Flk-1+/- mice by Pellino-1 intervention.

Chandra K Rednam1, Rickesha L Wilson1, Vaithinathan Selvaraju1, Muhammad T Rishi1,2, Mahesh Thirunavukkarasu1, Vladimir Coca-Soliz1,2, Rajesh Lakshmanan1, John A Palesty2, David W McFadden1, Nilanjana Maulik1.   

Abstract

OBJECTIVE: Reduced skin flap survival due to ischemia is a serious concern during reconstructive cosmetic surgery. The absence of VEGF and its receptors during ischemia may lead to flap failure. We identified Peli1, a 46-kDa protein, as a proangiogenic molecule and is directly regulated by VEGF. Therefore, we hypothesized that Peli1 acts downstream of Flk-1/VEGFR2 and aids in skin flap survival during ischemia.
METHODS: Scratch and matrigel assays were performed to observe cell proliferation, migration, and tube formation in vitro. Western blot analysis was carried out to detect the phosphorylation of Akt (p-Akt) and MAPKAPK2 (p-MK2) in HUVECs. The translational potential of Peli1 pretreatment in the rescue of skin flap tissue was studied in vivo using Flk-1+/- mice. Animals underwent dorsal ischemic skin flap surgery, and the tissue was collected on day 12 for analysis.
RESULTS: Western blot analysis revealed a direct relationship between Peli1 and VEGF, as demonstrated by loss-of-function and gain-of-function studies. In addition, pretreatment with Ad.Peli1 restored the phosphorylation of Akt and MK2 and improved the migration potential of Flk-1-knockdown cells. Ad.Peli1 pretreatment salvaged the ischemic skin flap of Flk-1+/- mice by increasing blood perfusion and reducing the inflammatory response and the extent of necrosis.
CONCLUSION: Our findings reveal that Peli1 is a proangiogenic molecule that acts downstream of VEGF-Flk-1 and restores angiogenesis and enhances skin flap survivability.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  Flk-1; Pellino-1; angiogenesis; distal flap necrosis; skin flap

Mesh:

Substances:

Year:  2017        PMID: 28177171     DOI: 10.1111/micc.12362

Source DB:  PubMed          Journal:  Microcirculation        ISSN: 1073-9688            Impact factor:   2.628


  5 in total

1.  Gene therapy with Pellino-1 improves perfusion and decreases tissue loss in Flk-1 heterozygous mice but fails in MAPKAP Kinase-2 knockout murine hind limb ischemia model.

Authors:  Mahesh Thirunavukkarasu; Seetur R Pradeep; Gopi Ukani; Salim Abunnaja; Mark Youssef; Diego Accorsi; Santosh Swaminathan; Sue Ting Lim; Virginia Parker; Jacob Campbell; Muhammad Tipu Rishi; J Alexander Palesty; Nilanjana Maulik
Journal:  Microvasc Res       Date:  2022-01-07       Impact factor: 3.750

2.  Multifaceted effects of astragaloside IV on promotion of random pattern skin flap survival in rats.

Authors:  Renjin Lin; Huanwen Chen; Daniel Callow; Shihen Li; Lei Wang; Shi Li; Long Chen; Jian Ding; Weiyang Gao; Huazi Xu; Jianzhong Kong; Kailiang Zhou
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

3.  Pellino-1 Regulates Immune Responses to Haemophilus influenzae in Models of Inflammatory Lung Disease.

Authors:  Bethany M Hughes; Charlotte S Burton; Abigail Reese; Maisha F Jabeen; Carl Wright; Jessica Willis; Nika Khoshaein; Elizabeth K Marsh; Peter Peachell; Shao C Sun; David H Dockrell; Helen M Marriott; Ian Sabroe; Alison M Condliffe; Lynne R Prince
Journal:  Front Immunol       Date:  2019-07-31       Impact factor: 7.561

Review 4.  The Emerging Roles of Pellino Family in Pattern Recognition Receptor Signaling.

Authors:  E Zhang; Xia Li
Journal:  Front Immunol       Date:  2022-02-07       Impact factor: 7.561

5.  Disruption of VEGF Mediated Flk-1 Signaling Leads to a Gradual Loss of Vessel Health and Cardiac Function During Myocardial Infarction: Potential Therapy With Pellino-1.

Authors:  Mahesh Thirunavukkarasu; Vaithinathan Selvaraju; Mandip Joshi; Vladimir Coca-Soliz; Leonidas Tapias; IbnalWalid Saad; Craig Fournier; Aaftab Husain; Jacob Campbell; Siu-Pok Yee; Juan A Sanchez; J Alexander Palesty; David W McFadden; Nilanjana Maulik
Journal:  J Am Heart Assoc       Date:  2018-09-18       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.